The Pharmacological Potential of Adenosine A(2A) Receptor Antagonists for Treating Parkinson’s Disease

The adenosine A(2A) receptor subtype is recognized as a non-dopaminergic pharmacological target for the treatment of neurodegenerative disorders, notably Parkinson’s disease (PD). The selective A(2A) receptor antagonist istradefylline is approved in the US and Japan as an adjunctive treatment to lev...

Descripción completa

Detalles Bibliográficos
Autores principales: Mori, Akihisa, Chen, Jiang-Fan, Uchida, Shinichi, Durlach, Cecile, King, Shelby M., Jenner, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000505/
https://www.ncbi.nlm.nih.gov/pubmed/35408767
http://dx.doi.org/10.3390/molecules27072366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000505/
https://www.ncbi.nlm.nih.gov/pubmed/35408767
http://dx.doi.org/10.3390/molecules27072366

Ejemplares similares